Quick Takeaways
- PRICE T ROWE ASSOCIATES INC /MD/ filed SCHEDULE 13G for SOLENO THERAPEUTICS INC COMMON STOCK (SLNO).
- Disclosed ownership: 5.2%.
- Date of event: 31 Mar 2025.
PRICE T ROWE ASSOCIATES INC /MD/ - 31 Mar 2025 SCHEDULE 13G Report for SOLENO THERAPEUTICS INC COMMON STOCK (SLNO)
- Filing Manager
- PRICE T ROWE ASSOCIATES INC /MD/
- Reporting Manager
- T. Rowe Price Associates, Inc.
- Security
- SOLENO THERAPEUTICS INC COMMON STOCK
- Symbol
- SLNO
- Shares outstanding
- 46,169,000 shares
- Disclosed Ownership
- 2,400,788 shares
- Ownership
- 5.2%
- Form type
- SCHEDULE 13G
- Filing time
- 14 May 2025, 10:45:26 UTC
- Date of event
- 31 Mar 2025
- Next filing
- 14 Aug 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"PRICE T ROWE ASSOCIATES INC /MD/ disclosed 5.2% ownership in SOLENO THERAPEUTICS INC COMMON STOCK (SLNO) on 31 Mar 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 May 2025, 10:45.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| T. Rowe Price Associates, Inc. | 5.2% | 2,400,788 | 2,379,067 | 0 | Ellen York | Vice President |